LSV Asset Management Has $2.67 Million Stock Position in Elevance Health, Inc. $ELV

LSV Asset Management raised its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 818.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 8,264 shares of the company’s stock after buying an additional 7,364 shares during the period. LSV Asset Management’s holdings in Elevance Health were worth $2,670,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ELV. Nilsine Partners LLC increased its stake in Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after buying an additional 29 shares during the last quarter. HBK Sorce Advisory LLC grew its holdings in shares of Elevance Health by 4.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock valued at $260,000 after acquiring an additional 31 shares in the last quarter. Detalus Advisors LLC increased its position in shares of Elevance Health by 1.8% in the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after acquiring an additional 31 shares during the last quarter. Forum Financial Management LP raised its holdings in Elevance Health by 1.1% during the third quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock worth $960,000 after acquiring an additional 33 shares in the last quarter. Finally, Activest Wealth Management boosted its position in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

NYSE ELV opened at $346.49 on Tuesday. The stock has a market cap of $76.47 billion, a PE ratio of 13.79, a P/E/G ratio of 1.93 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The firm has a 50-day moving average of $352.53 and a 200-day moving average of $332.74. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the prior year, the firm earned $3.84 EPS. The business’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.23%.

Analyst Upgrades and Downgrades

ELV has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price target on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Wells Fargo & Company dropped their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Guggenheim decreased their price objective on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Weiss Ratings lowered shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Finally, UBS Group set a $400.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $390.55.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.